- Home
- TIGR vs GLUE Comparison
TIGR vs GLUE Comparison
Compare TIGR & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIGR | GLUE |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TIGR | GLUE |
|---|---|---|
| Price | $7.18 | $17.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $14.20 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 1.8M | 831.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $75,622,000.00 |
| Revenue This Year | $79.26 | $84.02 |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | ★ $9.77 | $72.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.38 | $3.50 |
| 52 Week High | $13.55 | $25.77 |
Technical Indicators
Market Signals| Indicator | TIGR | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 41.05 |
| Support Level | N/A | $17.36 |
| Resistance Level | $8.77 | $18.66 |
| Average True Range (ATR) | 0.27 | 1.06 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 9.87 | 15.31 |
Price Performance
Historical ComparisonAbout TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.